N/A
Completed N=172
Post Market Safety Study and Effectiveness With Evolence in Subjects With Skin Color Types IV-VI
Non Therapeutic Body Modification
Source: ClinicalTrials.gov NCT00891774 ↗
Enrolled (actual)
172
Serious AEs
1.9%
Results posted
May 2011
Primary outcomePrimary: Safety Endpoint — 155; 0; 3 Participants
Summary
Approximately 165 subjects with Fitzpatrick Skin Color Types IV, V, and VI and a moderate to deep wrinkle between the corner of the nose and the corner of the mouth, will be treated with EVOLENCE® (an approved collagen filler) to smooth and flatten that wrinkle. They will be observed for 6 months to establish safety of the product as it relates to scarring and changes in skin pigment, and long term effectiveness.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Safety Endpoint |
155; 0; 3 | — |
| SECONDARY Reduction in Wrinkle Severity Score |
— | — |
| SECONDARY Investigator's Satisfaction of the Overall Treatment |
— | — |
| SECONDARY Subject's Satisfaction of the Overall Treatment |
— | — |
Eligibility Criteria
Inclusion Criteria
- >18 years of age
- moderate to deep wrinkle in the Naso-Labial fold
- Fitzpatrick Skin Type IV, V or VI
Exclusion Criteria
- Pregnant or nursing females
- Hx of allergies to related products
- history of keloids, active skin disease, or previous augmentation of the treatment area
Data sourced from ClinicalTrials.gov (NCT00891774). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.